NEO Earnings Prediction
The chart below shows how NEO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NEO sees a -3.98% change in stock price 10 days leading up to the earnings, and a +7.19% change 10 days following the report. On the earnings day itself, the stock moves by +2.73%. This data can give you a slight idea of what to expect for the next quarter's release.
NEO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
172.00M
10.57%
2.49%
Gross Margin
44.92%
3.38%
0.67%
Operating Margin
-8.26%
-26.05%
3.51%
Net Margin
-8.91%
-3.26%
-15.55%
EPS
-0.12
-9.09%
-14.29%
No Data Available
NEO Earnings Analysis
Neogenomics Inc Corporation (NEO.O) Earnings Conference Call
Positive
Earnings Per Share Beat: NeoGenomics reported earnings per share (EPS) of $0.04, exceeding expectations of $0.03.
Consistent Revenue Growth: The company achieved double-digit revenue growth for nine consecutive quarters, with Q4 revenue reaching $172 million, an 11% increase year-over-year.
EBITDA Turnaround Success: Adjusted EBITDA improved significantly, reaching $40 million in 2024, a turnaround from a negative $48 million in 2022.
Clinical Testing Growth: Clinical testing volumes increased by 9% compared to the previous year, with a 5% increase in revenue per test.
Improved Gross Margins: Adjusted gross margins improved to 48%, the highest in five years, reflecting operational efficiencies and a shift to higher-value tests.
NGS Revenue Growth: Next Generation Sequencing (NGS) revenue grew by 24% in Q4 and 34% for the year, now representing over 30% of total revenue.
Patient Service Expansion: The company served nearly 700,000 patients in 2024, positioning itself to achieve the goal of serving 1 million patients annually by 2028.
Long-Range Financial Growth Target: NeoGenomics raised its long-range financial plan, targeting annual top-line growth of 12% to 13%, excluding revenue from minimal residual disease (MRD) testing.
Strategic Collaboration in Hematology: The company announced a multi-year exclusive strategic collaboration with Adaptive for MRD monitoring, enhancing its leadership in hematology testing.
Customer Satisfaction Improvement: The Net Promoter Score improved to 74 in 2024, indicating increased customer satisfaction and trust in the company's services.
Negative
Pharma Budget Shortfall: The company did not see the expected pharma budget flush with year-end projects in the fourth quarter, which impacted revenue.
Sales Performance Limitations: There were limitations in selling new RaDaR contracts due to a preliminary injunction and negotiated settlement, affecting sales performance.
Increased Sales and Marketing Expenses: Sales and marketing expenses increased by 24%, reflecting continued investment but also indicating higher operational costs.
Rising Administrative Expenses: General and administrative expenses rose to $63 million, driven by higher technology costs and increased compensation, which could indicate rising operational inefficiencies.
Liquidity Concerns Highlighted: Cash and marketable securities decreased by 7% versus the prior year, suggesting potential liquidity concerns despite positive cash flow from operations.
First Quarter Revenue Outlook: The company anticipates first quarter revenues to be about 23% of full year revenue, indicating a slower start to the year compared to previous expectations.
NEO FAQs
How does NEO typically perform around its earnings report dates?
Is Neogenomics Inc (NEO) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NEO Earning Call Sentiment
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2024 Earnings Call Transcript
NEO.O
-0.7%Positive
The earnings call summary highlights strong financial performance, including a significant increase in adjusted EBITDA and improved margins. The Q&A section reveals positive momentum in NGS and new product launches, although there are some uncertainties in specific growth areas. The market cap suggests a moderate reaction, but the overall positive financials and optimistic outlook, despite some vague responses, indicate a likely positive stock price movement in the short term.
